TopoTarget enters marketing agreement with pharmaceutical firm  

2005.12.23
TopoTarget has entered an agreement with an unnamed pharmaceutical company to market TopoTarget's drug Savene in Austria and four Eastern European countries

TopoTarget, a Danish biopharmaceutical company which gained a listing on the Copenhagen Stock Exchange in June, has entered an agreement with an unnamed pharmaceutical company to market TopoTarget's drug Savene in Austria and four Eastern European countries. Under the terms of the agreement Savene will remain a TopoTarget brand.

Savene was assigned Orphan Medicinal Product designation by the European Medicines Evaluation Agency (EMEA) in September 2001, ensuring the drug ten years of European market exclusivity from the date of registration. Savene is used for the treatment of tissue damage following treatment with anti-cancer drugs. TopoTarget plans to launch Savene in Europe and the US towards the end of 2006. The news was reported by financial daily newspaper Børsen.

TopoTarget was established in 2000 and has grown both organically and through acquisitions. In 2002, the company acquired the UK cell cycle company Profilix, and in 2005 the German company G2M Cancer Drugs. TopoTarget is headquartered in Copenhagen and has operations in Oxford UK, and in Frankfurt and Karlsruhe, Germany.

Link > TopoTarget 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×